These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 9219142)

  • 1. Economic costs of cigarette smoking among adolescents in Nigeria.
    Olumide AO; Shmueli A; Adebayo ES; Omotade OO
    Z Gesundh Wiss; 2022; 30(7):1701-1712. PubMed ID: 35789784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The costs of crime associated with stimulant use in a Canadian setting.
    Enns B; Krebs E; DeBeck K; Hayashi K; Milloy MJ; Richardson L; Wood E; Nosyk B
    Drug Alcohol Depend; 2017 Nov; 180():304-310. PubMed ID: 28942287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monetary conversion factors for economic evaluations of substance use disorders.
    McCollister K; Yang X; Sayed B; French MT; Leff JA; Schackman BR
    J Subst Abuse Treat; 2017 Oct; 81():25-34. PubMed ID: 28847452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost and Return on Investment of a Work-Family Intervention in the Extended Care Industry: Evidence From the Work, Family, and Health Network.
    Dowd WN; Bray JW; Barbosa C; Brockwood K; Kaiser DJ; Mills MJ; Hurtado DA; Wipfli B
    J Occup Environ Med; 2017 Oct; 59(10):956-965. PubMed ID: 28763408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit-cost analysis of SBIRT interventions for substance using patients in emergency departments.
    Horn BP; Crandall C; Forcehimes A; French MT; Bogenschutz M
    J Subst Abuse Treat; 2017 Aug; 79():6-11. PubMed ID: 28673528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Return on Investment of a Work-Family Intervention: Evidence From the Work, Family, and Health Network.
    Barbosa C; Bray JW; Dowd WN; Mills MJ; Moen P; Wipfli B; Olson R; Kelly EL
    J Occup Environ Med; 2015 Sep; 57(9):943-51. PubMed ID: 26340282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public spending for illegal drug and alcohol treatment in hospitals: an EU cross-country comparison.
    Lievens D; Vander Laenen F; Christiaens J
    Subst Abuse Treat Prev Policy; 2014 Jun; 9():26. PubMed ID: 24981850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim versus standard methadone treatment: a benefit-cost analysis.
    Schwartz RP; Alexandre PK; Kelly SM; O'Grady KE; Gryczynski J; Jaffe JH
    J Subst Abuse Treat; 2014 Mar; 46(3):306-14. PubMed ID: 24239030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analysis of a multi-site prevention program: assessment of program costs and characterizing site-level variability.
    Corso PS; Ingels JB; Kogan SM; Foster EM; Chen YF; Brody GH
    Prev Sci; 2013 Oct; 14(5):447-56. PubMed ID: 23299559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits and costs of substance abuse treatment programs for state prison inmates: results from a lifetime simulation model.
    Zarkin GA; Cowell AJ; Hicks KA; Mills MJ; Belenko S; Dunlap LJ; Houser KA; Keyes V
    Health Econ; 2012 Jun; 21(6):633-52. PubMed ID: 21506193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.
    Zarkin GA; Bray JW; Aldridge A; Mills M; Cisler RA; Couper D; McKay JR; O'Malley S
    Med Care; 2010 May; 48(5):396-401. PubMed ID: 20393362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of interventions to treat opiate dependence : a review of the evidence.
    Doran CM
    Pharmacoeconomics; 2008; 26(5):371-93. PubMed ID: 18429655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"?
    Ettner SL; Huang D; Evans E; Ash DR; Hardy M; Jourabchi M; Hser YI
    Health Serv Res; 2006 Feb; 41(1):192-213. PubMed ID: 16430607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The costs of drug abuse consequences: a summary of research findings.
    French MT; Martin RF
    J Subst Abuse Treat; 1996; 13(6):453-66. PubMed ID: 9219142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicomponent model for substance abuse treatment. The Addiction Research and Treatment Corporation.
    Batson HW; Brown LS; Zaballero A; Faulcon-Gary J
    J Subst Abuse Treat; 1992; 9(2):177-81. PubMed ID: 1324991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the costs of substance abuse to the Medicaid hospital care program.
    Fox K; Merrill JC; Chang HH; Califano JA
    Am J Public Health; 1995 Jan; 85(1):48-54. PubMed ID: 7832261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DATStats: results from 85 studies using the Drug Abuse Treatment Cost Analysis Program.
    Roebuck MC; French MT; McLellan AT
    J Subst Abuse Treat; 2003 Jul; 25(1):51-7. PubMed ID: 14512108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financing strategies for drug abuse treatment programs.
    Zarkin GA; Galinis DN; French MT; Fountain DL; Ingram PW; Guyett JA
    J Subst Abuse Treat; 1995; 12(6):385-99. PubMed ID: 8749723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conceptual framework for estimating the social cost of drug abuse.
    French MT; Rachal JV; Hubbard RL
    J Health Soc Policy; 1991; 2(3):1-22. PubMed ID: 10170913
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.